Skip to main content
main-content

27.05.2022 | Original Article

Safety and Efficacy of Bendamustine and Rituximab (BR) Regimen in Indian Chronic Lymphocytic Leukaemia Patients

verfasst von: Ajay Gogia, Ritu Gupta, Atul Sharma, Lalit kumar, Lata rani, Saumyaranjan Mallick

Erschienen in: Indian Journal of Hematology and Blood Transfusion

Einloggen, um Zugang zu erhalten

Abstract

We investigated the safety and efficacy of bendamustine-rituximab (BR) in previously untreated symptomatic and advanced CLL patients, as there is no data available on BR from the Indian subcontinent.This retrospective study included 120 consecutive treatment naïve patients with CLL without del (17p), who were registered at the Department of Medical Oncology, AIIMS between January 2010 and July 2018. Bendamustine was given at a dose of 90 mg/m2 on days 1 and 2, combined with rituximab 375 mg/m2 rituximab on day 1, every 28 days for up to 6 courses. Event-free survival (EFS) was defined as the date of treatment to date of relapse, disease progression, or death due to any cause.The median age was 57 years (range: 30–75 years). As per the clinical Rai stage, 30 (25%) patients were in stage II, 42 (35%) were in stage III and 48 (40%) were in stage IV. ZAP70 was positive (> 20%) in 50%, CD 38 was positive (> 30%) in 33%, and CD49d was positive (> 30%) in 49% of cases. Beta-2 microglobulin (B2M) was elevated (≥ 3.5 mg/L) in 80% of cases. Fifty-five cases (50%, n = 110) were IGHV mutated. The mean number of cycles was 5 (1–6). The overall response rate (ORR) seen with BR was 90% and complete response was 45%. Median progression-free survival was 24 months with a median follow-up period of 29 months. Haemoglobin (< 10 g/dL), elevated B2 M, unmutated IGHV had a statistically significant adverse impact on EFS on univariate analysis but on multivariate analysis, only IGHV mutation status was found to had significance on EFS. The median EFS was 27 months in IGHV mutated versus 18 months in IGHV unmutated-CLL patients (p = 0.001). Grade 3/4 neutropenia, thrombocytopenia, anemia, and infections were observed in 30.6%, 8%, and 12% respectively. The most common non-hematological toxicity was skin rash which was grade 1/2 in 24 (20%) cases and grade 3/4 in 12 (10%) cases. This is the largest study from India to demonstrate the safety and efficacy of BR in symptomatic CLL patients. BR is an effective and safe regimen in the first-line treatment of CLL. Unmutated-CLL patients have inferior EFS than mutated-CLL patients. Skin toxicity was the most common adverse effect seen in our population which was observed in around one-third of cases.
Literatur
2.
Zurück zum Zitat Keating MJ, O’Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079–4088 CrossRef Keating MJ, O’Brien S, Albitar M et al (2005) Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079–4088 CrossRef
3.
Zurück zum Zitat Fischer K, Bahlo J, Fink AM et al (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127(2):208–215 CrossRef Fischer K, Bahlo J, Fink AM et al (2016) Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127(2):208–215 CrossRef
4.
Zurück zum Zitat Polizzotto MN, Tam CS, Milner A et al (2006) The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 107(4):773–780 CrossRef Polizzotto MN, Tam CS, Milner A et al (2006) The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders. Cancer 107(4):773–780 CrossRef
5.
Zurück zum Zitat Gill S, Carney D, Ritchie D et al (2010) The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol Off J Eur Soc Med Oncol 21(2):331–334 CrossRef Gill S, Carney D, Ritchie D et al (2010) The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy. Ann Oncol Off J Eur Soc Med Oncol 21(2):331–334 CrossRef
6.
Zurück zum Zitat Gogia A, Sharma A, Raina V et al (2012) Assessment of 285 cases of chronic lymphocytic leukemia seen at a single large tertiary center in Northern India. Leuk Lymphoma 53(10):1961–1965 CrossRef Gogia A, Sharma A, Raina V et al (2012) Assessment of 285 cases of chronic lymphocytic leukemia seen at a single large tertiary center in Northern India. Leuk Lymphoma 53(10):1961–1965 CrossRef
7.
Zurück zum Zitat Foon KA, Boyiadzis M, Land SR et al (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27(4):498–503 CrossRef Foon KA, Boyiadzis M, Land SR et al (2009) Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27(4):498–503 CrossRef
8.
Zurück zum Zitat Smolej L, Brychtova Y, Doubek M et al (2014) Low-dose FCR Is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma updated results of project Q-lite by Czech CLL study group. Blood 124(21):4670–4670 CrossRef Smolej L, Brychtova Y, Doubek M et al (2014) Low-dose FCR Is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma updated results of project Q-lite by Czech CLL study group. Blood 124(21):4670–4670 CrossRef
9.
Zurück zum Zitat Fischer K, Cramer P, Busch R et al (2012) Bendamustine in Combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 30(26):3209–3216 CrossRef Fischer K, Cramer P, Busch R et al (2012) Bendamustine in Combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group. J Clin Oncol 30(26):3209–3216 CrossRef
10.
Zurück zum Zitat Eichhorst B, Fink A-M, Bahlo J et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928–942 CrossRef Eichhorst B, Fink A-M, Bahlo J et al (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928–942 CrossRef
11.
Zurück zum Zitat Panovská A, Němcová L, Nekvindová L et al (2020) Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: the GO-CLLEAR study by the Czech CLL study group. Hematol Oncol 38(4):509–516 CrossRef Panovská A, Němcová L, Nekvindová L et al (2020) Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: the GO-CLLEAR study by the Czech CLL study group. Hematol Oncol 38(4):509–516 CrossRef
12.
Zurück zum Zitat Knauf W, Abenhardt W, Dörfel S et al (2015) Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany—data from the Prospective tumour registry lymphatic neoplasms. Hematol Oncol 33(1):15–22 CrossRef Knauf W, Abenhardt W, Dörfel S et al (2015) Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany—data from the Prospective tumour registry lymphatic neoplasms. Hematol Oncol 33(1):15–22 CrossRef
13.
Zurück zum Zitat Rai KR, Sawitsky A, Cronkite EP et al (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219–234 CrossRef Rai KR, Sawitsky A, Cronkite EP et al (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219–234 CrossRef
15.
Zurück zum Zitat Hernández JA, Land KJ, McKenna RW (1995) Leukemias, myeloma and other lymphoreticular neoplasms. Cancer 75(1):381–394 CrossRef Hernández JA, Land KJ, McKenna RW (1995) Leukemias, myeloma and other lymphoreticular neoplasms. Cancer 75(1):381–394 CrossRef
16.
Zurück zum Zitat Smith A, Howell D, Patmore R, Jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer 105(11):1684–1692 CrossRef Smith A, Howell D, Patmore R, Jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer 105(11):1684–1692 CrossRef
17.
Zurück zum Zitat Tejaswi V, Lad DP, Jindal NP et al (2020) Chronic lymphocytic leukemia: real-world data from India. JCO Glob Oncol 22(6):866–872 CrossRef Tejaswi V, Lad DP, Jindal NP et al (2020) Chronic lymphocytic leukemia: real-world data from India. JCO Glob Oncol 22(6):866–872 CrossRef
18.
Zurück zum Zitat Saikia N, Moradhvaj BJK (2016) Gender difference in health-care expenditure: evidence from India human development survey. PLoS ONE 11(7):e0158332 CrossRef Saikia N, Moradhvaj BJK (2016) Gender difference in health-care expenditure: evidence from India human development survey. PLoS ONE 11(7):e0158332 CrossRef
19.
Zurück zum Zitat Ganguly S, Kinsey S, Bakhshi S (2021) Childhood cancer in India. Cancer Epidemiol 71(Pt B):101679 CrossRef Ganguly S, Kinsey S, Bakhshi S (2021) Childhood cancer in India. Cancer Epidemiol 71(Pt B):101679 CrossRef
20.
Zurück zum Zitat Gentile M, Zirlik K, Ciolli S et al (2016) Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. Eur J Cancer 60:154–165 CrossRef Gentile M, Zirlik K, Ciolli S et al (2016) Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. Eur J Cancer 60:154–165 CrossRef
21.
Zurück zum Zitat Laurenti L, Innocenti I, Autore F et al (2015) Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: a retrospective analysis of real-life practice in Italian hematology departments. Leuk Res 39(10):1066–1070 CrossRef Laurenti L, Innocenti I, Autore F et al (2015) Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: a retrospective analysis of real-life practice in Italian hematology departments. Leuk Res 39(10):1066–1070 CrossRef
22.
Zurück zum Zitat Günther G, Bartels S, Tessen H-W, Sterchele JA (2012) Real-world efficacy and safety of bendamustine with or without rituximab in treatment-naïve patients with chronic lymphocytic leukemia: retrospective analysis of a german registry. Blood 120(21):2905 CrossRef Günther G, Bartels S, Tessen H-W, Sterchele JA (2012) Real-world efficacy and safety of bendamustine with or without rituximab in treatment-naïve patients with chronic lymphocytic leukemia: retrospective analysis of a german registry. Blood 120(21):2905 CrossRef
23.
Zurück zum Zitat Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet 376(9747):1164–1174 CrossRef Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. The Lancet 376(9747):1164–1174 CrossRef
24.
Zurück zum Zitat Rossi D, Terzi-di-Bergamo L, De Paoli L et al (2015) Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood J Am Soc Hematol 126(16):1921–1924 Rossi D, Terzi-di-Bergamo L, De Paoli L et al (2015) Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood J Am Soc Hematol 126(16):1921–1924
25.
Zurück zum Zitat Moia R, Patriarca A, Schipani M, Gaidano G (2021) The biology of chronic lymphocytic leukemia: diagnostic and prognostic implications. Cancer J Sudbury Mass 27(4):266–274 CrossRef Moia R, Patriarca A, Schipani M, Gaidano G (2021) The biology of chronic lymphocytic leukemia: diagnostic and prognostic implications. Cancer J Sudbury Mass 27(4):266–274 CrossRef
26.
Zurück zum Zitat Špaček M, Obrtlíková P, Hrobková S et al (2019) Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. Leuk Res 79:17–21 CrossRef Špaček M, Obrtlíková P, Hrobková S et al (2019) Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. Leuk Res 79:17–21 CrossRef
27.
Zurück zum Zitat Malipatil B, Ganesan P, Sundersingh S, Sagar TG (2011) Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. HematolOncol Stem Cell Ther 4(4):157–160 CrossRef Malipatil B, Ganesan P, Sundersingh S, Sagar TG (2011) Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect. HematolOncol Stem Cell Ther 4(4):157–160 CrossRef
28.
Zurück zum Zitat Gogia A, Kumar S, Kumar L et al (2021) Safety and efficacy of bendamustine-rituximab in treatment naïve symptomatic follicular lymphoma: an institutional analysis. Indian J Hematol Blood Transfus 37(1):169–170 CrossRef Gogia A, Kumar S, Kumar L et al (2021) Safety and efficacy of bendamustine-rituximab in treatment naïve symptomatic follicular lymphoma: an institutional analysis. Indian J Hematol Blood Transfus 37(1):169–170 CrossRef
29.
Zurück zum Zitat Jo T, Horio K, Shigematsu K, Toriyama F (2014) Skin Rash with eosinophilia resulting from bendamustine plus rituximab treatment: a hematological and pathological analysis of 5 cases. Blood 124(21):5376–5376 CrossRef Jo T, Horio K, Shigematsu K, Toriyama F (2014) Skin Rash with eosinophilia resulting from bendamustine plus rituximab treatment: a hematological and pathological analysis of 5 cases. Blood 124(21):5376–5376 CrossRef
30.
Zurück zum Zitat Carilli A, Favis G, Sundharkrishnan L, Hajdenberg J (2014) Severe dermatologic reactions with bendamustine: a case series. Case Rep Oncol 7(2):465–470 CrossRef Carilli A, Favis G, Sundharkrishnan L, Hajdenberg J (2014) Severe dermatologic reactions with bendamustine: a case series. Case Rep Oncol 7(2):465–470 CrossRef
31.
Zurück zum Zitat Weed RI (1965) Exaggerated delayed hypersensitivity to mosquito bites in chronic lymphocytic leukemia. Blood 26:257–268 CrossRef Weed RI (1965) Exaggerated delayed hypersensitivity to mosquito bites in chronic lymphocytic leukemia. Blood 26:257–268 CrossRef
33.
Zurück zum Zitat Mato A, Nabhan C, Lamanna N et al (2020) (2020) The connect CLL registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv 4(7):1407–1418 CrossRef Mato A, Nabhan C, Lamanna N et al (2020) (2020) The connect CLL registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites. Blood Adv 4(7):1407–1418 CrossRef
Metadaten
Titel
Safety and Efficacy of Bendamustine and Rituximab (BR) Regimen in Indian Chronic Lymphocytic Leukaemia Patients
verfasst von
Ajay Gogia
Ritu Gupta
Atul Sharma
Lalit kumar
Lata rani
Saumyaranjan Mallick
Publikationsdatum
27.05.2022
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-022-01544-y

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.